ImmuneBridge
Next generation allogenic NK cell therapy platform
ImmuneBridge is developing the next generation of allogeneic cellular medicines, starting with NK cell-based immunotherapies. ImmuneBridge’s proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency—to create a consistent and abundant cellular source for immunotherapies. Based in San Francisco, ImmuneBridge is led by Nina Horowitz, CEO and Rui Tostoes, CTO and backed my M Ventures, Insight Partners, NFX, One Way Ventures, LongGame, T.Rx Capital and others.
